Skyviews Life Science

one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of advanced tissue reconstruction technologies tailored for the reconstructive and plastic surgery markets. The company focuses on tissue engineering, creating injectable 3D scaffolds that facilitate the reconstruction of lost soft tissue volumes due to tumor ablation, disease, trauma, or aesthetic needs. These innovative scaffolds can be administered through thin cannulas, which helps reduce both intervention and recovery times for patients, addressing the challenges associated with the natural repair of three-dimensional soft tissues.

Tropic Biosciences UK Ltd, established in 2016 and based in Norwich, is a biotechnology company specializing in the development of commercial tropical crops. It employs advanced plant breeding and non-GMO gene editing techniques to create high-performing varieties, catering primarily to the coffee and banana industries. The company's mission is to promote grower wellbeing, consumer health, and sustainable environmental practices through its innovative, non-GMO methods, which significantly accelerate the breeding process to meet growing food demands and local community needs.

one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Aleph Farms Limited is an innovative food technology company based in Ashdod, Israel, specializing in cellular agriculture to produce clean meat. Founded in 2017, Aleph Farms focuses on sustainable food production by developing methods to grow animal products directly from non-genetically modified animal cells, utilizing proprietary three-dimensional bioprinting technologies. The company made significant strides in the industry by unveiling the world's first cultivated thin-cut steak in 2018, followed by the first cultivated ribeye steak in 2021 and cultivated collagen in 2022. Under its product brand Aleph Cuts, its inaugural offering, the Petit Steak, is crafted from non-modified cells sourced from a premium Angus cow, allowing production without animal slaughter. Aleph Farms has garnered recognition for its commitment to climate leadership, including a net zero pledge made in 2020, earning accolades from prominent organizations like the World Economic Forum and the United Nations.

Aleph Farms Limited is an innovative food technology company based in Ashdod, Israel, specializing in cellular agriculture to produce clean meat. Founded in 2017, Aleph Farms focuses on sustainable food production by developing methods to grow animal products directly from non-genetically modified animal cells, utilizing proprietary three-dimensional bioprinting technologies. The company made significant strides in the industry by unveiling the world's first cultivated thin-cut steak in 2018, followed by the first cultivated ribeye steak in 2021 and cultivated collagen in 2022. Under its product brand Aleph Cuts, its inaugural offering, the Petit Steak, is crafted from non-modified cells sourced from a premium Angus cow, allowing production without animal slaughter. Aleph Farms has garnered recognition for its commitment to climate leadership, including a net zero pledge made in 2020, earning accolades from prominent organizations like the World Economic Forum and the United Nations.

Cellares Corporation, founded in 2019 and based in South San Francisco, California, specializes in the development of cell therapies for cancer treatment. The company addresses significant manufacturing challenges associated with these therapies, which are often produced on a per-patient basis, leading to high costs and limited availability. Cellares is pioneering the Cell Shuttle, an automated, closed end-to-end manufacturing solution designed to enhance the scalability and efficiency of cell therapy production. This innovative system allows for the simultaneous production of ten times more patient doses compared to traditional manual methods, while also reducing process failure rates by three-fold and lowering manufacturing costs by up to 70 percent. By providing flexible and scalable manufacturing options, Cellares aims to accelerate the delivery of life-saving therapies to patients in need and support the broader biopharmaceutical industry in meeting global demand for these treatments.

MIRAI FOODS is a cellular agriculture startup developing cultivated beef.

Ukko is a biotechnology company focused on enhancing the quality of life for individuals affected by food allergies and disorders. The company utilizes a computational engineering platform that employs artificial intelligence, immunology, and protein engineering to redesign food allergens into therapeutics that are both safe and effective. By creating a comprehensive, clinically validated map of the molecular structures associated with food allergies, Ukko reveals critical insights into the biological mechanisms governing human-food interactions. This innovative approach enables the development of new protein versions that do not provoke an immune response, providing a novel strategy for treating protein-based allergies.

Tropic Biosciences UK Ltd, established in 2016 and based in Norwich, is a biotechnology company specializing in the development of commercial tropical crops. It employs advanced plant breeding and non-GMO gene editing techniques to create high-performing varieties, catering primarily to the coffee and banana industries. The company's mission is to promote grower wellbeing, consumer health, and sustainable environmental practices through its innovative, non-GMO methods, which significantly accelerate the breeding process to meet growing food demands and local community needs.

one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.

COMPASS Pathways is a UK-based mental health care company dedicated to accelerating patient access to innovative treatments for mental health challenges. The company focuses on developing psilocybin therapy, administered in conjunction with psychological support, for patients with treatment-resistant depression who have not responded to conventional treatments.